Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Investor's Business Daily · ALLISON GATLIN ·
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.
Hims & Hers Health (HIMS) inked a deal with Eli Lilly (LLY) on Friday to sell the company's obesity drugs, further entrenching itself in the branded GLP-1 space. Hims stock surged more than 8% to 26.03, while Lilly stock dipped more than 1% to 1,353. The deal will sees Hims sell Lilly's Zepbound and Foundayo on its telehealth platform. It…
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Read the full story at Investor's Business Daily · All coverage of this story